On Monday we published a detailed guide for international nutraceutical companies conducting clinical studies in India.
The question we hear most from international sponsors considering India for the first time:
"Will the data actually be accepted by our regulator?"
The answer is yes — but the conditions matter more than most sponsors realize before they start.

#Nutraceuticals #ClinicalResearch #India #CRO #FDA #EMA #TGA #DietarySupplements #InternationalClinicalTrials

https://genelifecr.blogspot.com/2026/06/conducting-nutraceutical-clinical.html

Conducting Nutraceutical Clinical Trials in India for International Regulatory Submissions: What Sponsors Need to Know

Nutraceutical clinical trials in India for FDA, EMA, and global regulatory submissions by Genelife Clinical Research.

This article explains what international regulatory acceptability actually requires — and what to look for in a CRO partner that can deliver it.

#Nutraceuticals #ClinicalTrials #India #CRO #FDA #EMA #InternationalResearch #DietarySupplements

https://genelifecr.blogspot.com/2026/06/conducting-nutraceutical-clinical.html

Conducting Nutraceutical Clinical Trials in India for International Regulatory Submissions: What Sponsors Need to Know

Nutraceutical clinical trials in India for FDA, EMA, and global regulatory submissions by Genelife Clinical Research.

The global regulatory direction for nutraceuticals is clear: prove it clinically, or lose the claim.

The problem: clinical trials in the US and EU are expensive enough that the ROI is genuinely difficult.

The solution more international nutraceutical companies are finding: conduct the study in India.

#Nutraceuticals #ClinicalTrials #India #CRO #FDA #EMA #DietarySupplements #EvidenceBased
https://genelifecr.blogspot.com/2026/05/the-evidence-gap-in-nutraceuticals-why.html

The Evidence Gap in Nutraceuticals: Why International Companies Are Turning to India to Close It

India is a preferred destination for nutraceutical evidence generation through clinical studies, RWE and cost-effective research capabilities.

Nokia Shares Hold Gains After Sharp Intraday Rally, Volatility Moderates Near $16.65

Nokia Extends Positive Momentum During Active Session Nokia Corporation shares traded higher during the observed session, with price reach...

Blogger

The era of marketing on plausibility and tradition alone is ending. Clinical evidence — rigorous, human, controlled — is becoming the price of credible market positioning.
The question for international nutraceutical companies isn't whether to generate that evidence. It's how to do it at a cost and speed that makes commercial sense.
#Nutraceuticals #ClinicalResearch #DietarySupplements #India #CRO #EvidenceBased #FDA #EMA #TGA

https://genelifecr.blogspot.com/2026/05/the-evidence-gap-in-nutraceuticals-why.html

The Evidence Gap in Nutraceuticals: Why International Companies Are Turning to India to Close It

India is a preferred destination for nutraceutical evidence generation through clinical studies, RWE and cost-effective research capabilities.

Monday's article breaks down the evidence gap, why it's closing, and why India is where international nutraceutical companies are choosing to close it.

#Nutraceuticals #ClinicalResearch #DietarySupplements #India #CRO #EvidenceBased #FDA #EMA #TGA

https://genelifecr.blogspot.com/2026/05/the-evidence-gap-in-nutraceuticals-why.html

The Evidence Gap in Nutraceuticals: Why International Companies Are Turning to India to Close It

India is a preferred destination for nutraceutical evidence generation through clinical studies, RWE and cost-effective research capabilities.

Good Lighting Starts Here | Cinematic Lighting in Unreal Engine https://www.youtube.com/watch?v=qn1qlgSBQsE

#unrealengine #gamedev #gamedevelopment #indiedev #ema

Good Lighting Starts Here | Cinematic Lighting in Unreal Engine

YouTube